Skip to main content
SpringerLink
Log in

Increased apoptosis and increased clonogenic survival of 12V-H-ras transformed rat fibroblasts in response to cisplatin

  • Published:
Apoptosis Aims and scope Submit manuscript

Abstract

Mutationally activated Ras is involved in tumor progression and likely also in drug resistance. Using survival, viability and apoptosis assays, we have here compared the cisplatin sensitivities of FR3T3 rat fibroblasts and a 12V-H-ras transformed subline (Ras2:3). Around 24 h after cisplatin treatment Ras2:3 cells showed higher apoptosis levels and lower viability than FR3T3. This increased sensitivity correlated with weaker cisplatin-induced activation of Jun N-terminal kinase (JNK). In contrast to apoptosis assays, colony formation assays showed that Ras2:3 were more resistant to cisplatin than were FR3T3. This was partly due to the increased cisplatin sensitivity of FR3T3 seeded at low densities, as required in colony formation assays. In addition, Ras2:3 cisplatin survivors had a higher relative proliferative capacity. Cell cycle analyses showed that FR3T3 cells initially responded with a dose-dependent G2 arrest, while Ras2:3 accumulated in S-phase. Experiments with an anti-apoptotic mutant of MEKK1 suggested that the apoptotic response of Ras2:3 cells is not specific to the S-phase fraction. In summary, the cisplatin response of ras-transformed fibroblasts is distinct from that of parental cells, in that they show increased apoptosis, a different cell cycle response and increased post-treatment proliferative capacity. The results illustrate the need to carefully consider methods and protocols for in vitro studies on chemotherapy sensitivity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998; 34: 1535–1542.

    PubMed  Google Scholar 

  2. Zamble DB, Jacks T, Lippard SJ. p53-dependent and-independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci USA 1998; 95: 6163–6168.

    PubMed  Google Scholar 

  3. Ormerod MG, Orr RM, Peacock JH. The role of apoptosis in cell killing by cisplatin: A flow cytometric study. Br J Cancer 1994; 69: 93–100.

    PubMed  Google Scholar 

  4. Wilkins DE, Ng CE, Raaphorst GP. Cell cycle perturbations in cisplatin-sensitive and resistant human ovarian carcinoma cells following treatment with cisplatin and low dose rate irradiation. Cancer Chemother Pharmacol 1997; 40: 159–166.

    PubMed  Google Scholar 

  5. Vaisman A, Varchenko M, Said I, Chaney SG. Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 1997; 2: 54–64.

    Google Scholar 

  6. Sanchez-Perez I, Murguia JR, Perona R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 1998; 16: 533–540.

    PubMed  Google Scholar 

  7. Isonishi S, Hom DK, Thiebaut FB, et al. Expression of the c-Ha-ras oncogene in mouse NIH3T3 cells induces resistance to cisplatin. Cancer Res 1991; 51: 5903–5909.

    PubMed  Google Scholar 

  8. Warenius HM, Seabra LA, Maw P. Sensitivity to cisdiamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not c-raf-1 protein. Int J Cancer 1996; 67: 224–231.

    PubMed  Google Scholar 

  9. Jansen B, Schlagbauer-Wadl H, Eichler HG, et al. Activated NRas contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis. Cancer Res 1997; 57: 362–365.

    PubMed  Google Scholar 

  10. Basu A, Cline JS. Oncogenic transformation alters cisplatininduced apoptosis in rat embryo fibroblasts. Int J Cancer 1995; 63: 597–603.

    PubMed  Google Scholar 

  11. Holford J, Rogers P, Kelland LR. ras mutation and platinum resistance in human ovarian carcinomas in vitro. Int J Cancer 1998; 77: 94–100.

    PubMed  Google Scholar 

  12. Molin M, Shoshan MC, Öhman-Forslund K, Linder S, Akusjärvi G. Two novel adenovirus vector systems permitting regulated protein expression in gene transfer experiments. J Virol 1998; 72: 8358–8361.

    PubMed  Google Scholar 

  13. James GL, Goldstein JL, Brown MS, et al. Benzodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animal cells. Science 1993; 260: 1937–1942.

    Google Scholar 

  14. Widmann C, Gerwins P, Lassignal Johnson N, Jarpe MB, Johnson GL. MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis. Mol Cell Biol 1998; 18: 2416–2429.

    PubMed  Google Scholar 

  15. Bos JL. ras oncogenes in human cancer—a review. Cancer Res 1989; 49: 4682–4689.

    PubMed  Google Scholar 

  16. Joneson T, Bar-Sagi D. Ras effectors and their role in mitogenesis and oncogenesis. J Mol Medicine 1997; 75: 587–593.

    Google Scholar 

  17. ChenCY, Liou J, Forman LW, FallerDV. Differential regulation of discrete apoptotic pathways by Ras. J Biol Chem 1998; 273: 16700–16709.

    PubMed  Google Scholar 

  18. Sklar MD. Increased resistance to cis-diamminedichloroplatinum( II) in NIH3T3 cells transformed by ras oncogenes. Cancer Res 1988; 48: 793–797.

    PubMed  Google Scholar 

  19. Perez RP, Hamaguchi K, Tracey PA, Handel LM, Hamilton LM, Godwin AK. Transformation of rat ovarian epithelial and Rat-1 fibroblast cell lines by RAST24 does not influence cisplatin sensitivity. Cancer Res 1993; 53: 3771–3775.

    PubMed  Google Scholar 

  20. Russell M, Lange-Carter CA, Johnson GL. Direct interaction between Ras and the kinase domain of mitogen-activated protein kinase kinase kinase (MEKK1), J Biol Chem 1995; 270: 11757–11760.

    PubMed  Google Scholar 

  21. Ohmori M, Shirasawa S, Furuse M, Okumura K, Sasazuki T. Activated Ki-ras enhances sensitivity of ceramide-induced apoptosis without c-Jun NH2-terminal kinase/stress-activated protein kinase or extracellular signal-regulated kinase activation in human colon cancer cells. Cancer Res 1997; 57: 4714–4717.

    PubMed  Google Scholar 

  22. Butterfield L, Storey B, Maas L, Heasley LE. c-Jun NH2-terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation. J Biol Chem 1997; 272: 10110–10116.

    Article  PubMed  Google Scholar 

  23. Wisdom R, Johnson RS, Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J 1999; 18: 188–197.

    PubMed  Google Scholar 

  24. Potapova O, Haghighi A, Bost F, et al. The Jun kinase/stressactivated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 1997; 272: 14041–14044.

    Article  PubMed  Google Scholar 

  25. Garrido C, Ottavi P, Fromentin A, et al. HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res 1997; 57: 2661–2667.

    PubMed  Google Scholar 

  26. Dimanche-Boitrel MT, Micheau O, Hammann A, Eymin B, Chauffert B, Solary E. Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. Int J Cancer 1998; 77: 796–802.

    PubMed  Google Scholar 

  27. Sorenson CM, Barry MA, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990; 82: 749–755.

    PubMed  Google Scholar 

  28. Eastman A. Activation of programmed cell death by anticancer agents: Cisplatin as a model system. Cancer Cells 1990; 2: 275–280.

    PubMed  Google Scholar 

  29. Brown JM, Wouters BG. Does apoptosis contribute to tumor cell sensitivity to anticancer agents? In: Hickman JA, Dive C, eds. Apoptosis and Cancer Chemotherapy. Totowa, NJ, USA: Humana Press, 1999: 1–20.

  30. Waldman T, Zhang Y, Dillehay L, et al. Cell-cycle arrest versus cell death in cancer therapy. Nature Medicine 1997; 3: 1034–1036.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiumhemmet's Research Laboratory, Cancer Center Karolinska, Karolinska Institute and Hospital, S-171 76, Stockholm, Sweden

    K. Viktorsson, S. Linder & M. C. Shoshan

  2. Department of Medical Radiobiology, Karolinska Institute, S-171 76, Stockholm, Sweden

    T. Heiden

  3. Department of Medical Biochemistry and Microbiology, BMC, Uppsala University, S-751 23, Uppsala, Sweden

    M. Molin & G. Akusjärvi

Authors
  1. K. Viktorsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Heiden
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Molin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Akusjärvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Linder
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. C. Shoshan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Viktorsson, K., Heiden, T., Molin, M. et al. Increased apoptosis and increased clonogenic survival of 12V-H-ras transformed rat fibroblasts in response to cisplatin. Apoptosis 5, 355–367 (2000). https://doi.org/10.1023/A:1009639726168

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009639726168

Search

Navigation